1-烯丙氧羰基-4-哌啶酮 | 306296-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-烯丙氧羰基-4-哌啶酮
• 中文别名: 1-N-alloc-4-哌啶酮
• 英文名称: N-alloc-4-piperidone
• 英文别名: 1-allyloxycarbonylpiperidin-4-one；1-N-Alloc-4-piperidone；prop-2-enyl 4-oxopiperidine-1-carboxylate
• CAS: 306296-67-3
• 化学式: C₉H₁₃NO₃
• mdl: MFCD02183578
• 分子量: 183.207
• InChiKey: TUEIRODWNWORRI-UHFFFAOYSA-N

物化性质

• 沸点：
  287.1±40.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-烯丙氧羰基-4-哌啶酮 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 91.0h， 生成 3-Isobutyl-2,5-dioxo-1-propyl-1,4,9-triaza-spiro[5.5]undecane-9-carboxylic acid allyl ester
  参考文献：
  名称：

  使用新的spirodiketopiperazine支架设计，合成和生物学评估组合文库。发现新型有效和选择性的低分子量CCR5拮抗剂。

  摘要：

  我们之前曾报道发现有几种螺二酮哌啶衍生物作为具有抗HIV活性的有效CCR5拮抗剂。在本文中，我们详细描述了使用组合化学方法鉴定这些先导化合物的方法。基于G蛋白偶联受体（GPCR）的优先结构的概念，设计了一种新型的螺二酮哌嗪骨架。通过Ugi反应，顺序转化和环化裂解，可以从容易制备的异腈树脂中以高收率获得可接受的高纯度新骨架。通过测量初始文库中每种化合物对MIP-1alpha刺激的细胞内钙动员的抑制活性，发现了几种化合物显示出适度但有选择性的CCR5拮抗活性。

  DOI：

  10.1021/jm060051s
• 作为产物：
  描述：

  4-哌啶酮缩乙二醇 在 C₂H₆O₃PPol 、 potassium carbonate 作用下， 以 水 、 丙酮 为溶剂， 反应 9.0h， 生成 1-烯丙氧羰基-4-哌啶酮
  参考文献：
  名称：

  Highly Functionalised Sulfur-Based Silica Scavengers for the Efficient Removal of Palladium Species from Active Pharmaceutical Ingredients

  摘要：

  The use of multidentate sulfur-based silica scavengers 1, 2, and 3 as highly effective adsorbents for the removal of precious metals, specifically palladium residues in this paper, from highly functionalised synthetic intermediates and APIs is described. The synthesis and purification of the polar and electron-rich reaction products, containing multiple functional groups, from palladium-catalysed removals of commonly used protecting groups such as benzyl, benzyloxycarbonyl, and allyloxycarbonyl and Sonogashira, Suzuki, Heck, and Buchwald-Hartwig coupling reactions is reported. The significant levels of residual palladium species, typically associated with these reaction products, are successfully and rapidly removed to below acceptable regulatory levels, of less than 5 ppm, by simple, unoptimised treatment with the designed silica scavengers at room temperature. Performance aspects, including broad solvent compatibility, excellent stability, and high metal affinity, combined with large-scale availability, ease of handling, and minimal loss of API make these silica scavengers particularly useful to process development groups.

  DOI：

  10.1021/op7000172
• 作为试剂：
  描述：

  4-bromo-2-(4-fluorophenyl)-3-(2-fluoropyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 以 1-烯丙氧羰基-4-哌啶酮 为溶剂， 以6%的产率得到4-(1-Allyloxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(2-fluoropyridin-4-yl)-1 H-pyrrole
  参考文献：
  名称：

  Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses

  摘要：

  公开号：

  EP1070711B1

文献信息

• [EN] NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS CONTENANT UN CYCLE AZOTÉ POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：WEINGARTEN M DAVID

  公开号：WO2012135669A1

  公开（公告）日：2012-10-04

  The invention provides compounds, pharmaceutical compositions and methods of treatment of inflammatory disorders including a compound of Formula I, or its pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative or prodrug wherein R1, R2, R3, R4, X, Y, W, Z and Q are as defined herein.

  这项发明提供了化合物、药物组合物和治疗炎症性疾病的方法，包括式I的化合物，或其药用可接受的盐、酯、药用可接受的衍生物或前药，其中R1、R2、R3、R4、X、Y、W、Z和Q如本文所定义。
• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• GPR119 Receptor Agonists
  申请人：Erickson Shawn David

  公开号：US20090286812A1

  公开（公告）日：2009-11-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  提供以下公式(I)的化合物： 以及可药用的接受盐，其中取代基如说明书中所披露。这些化合物以及含有它们的药物组合物可用于治疗代谢性疾病和障碍，例如，2型糖尿病。
• [EN] SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS<br/>[FR] TRIAZOLES AMINO-SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE CHITINASE HUMAINE
  申请人：ONCOARENDI THERAPEUTICS SP Z O O

  公开号：WO2017037670A1

  公开（公告）日：2017-03-09

  Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

  揭示了一种氨基三唑化合物，其带有一个被杂环环取代的哌啶环。这些化合物是酸性哺乳动物几丁质酶和几丁三糖酶的抑制剂。还公开了使用这些化合物治疗由过敏原引起的哮喘反应，以及急性和慢性炎症性疾病、自身免疫疾病、牙科疾病、神经系统疾病、代谢性疾病、肝脏疾病、多囊卵巢综合征、子宫内膜异位症和癌症的方法。
• [EN] AUTOTAXIN INHIBITORS<br/>[FR] INHIBITEURS DE L'AUTOTAXINE
  申请人：MERCK PATENT GMBH

  公开号：WO2010112124A1

  公开（公告）日：2010-10-07

  The present invention relates to compounds according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.

  本发明涉及按照式(I)的化合物作为自体脂肪酶抑制剂，以及利用这种化合物治疗和/或预防由增加的溶酶磷脂酸水平和/或自体脂肪酶的激活引起、介导和/或传播的生理和/或病理条件，特别是不同癌症的治疗。